Cargando…
812. Case–Control Trial to Evaluate the Cytokine Response to the Use of Capsule Thalidomide in Erythema Nodosum Leprosum in Leprosy Patients
BACKGROUND: Leprosy is a chronic granulomatous disease caused by Mycobacterium leprae. Type II lepra reaction or Erythema Nodosum Leposum is a Type III hypersentivity immune response during the chronic course of the illness. This immune response presents as systemic symptoms and neutrophilic leukocy...
Autores principales: | Chopra, Ajay, Mitra, Debdeep, Mitra, Barnali |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254824/ http://dx.doi.org/10.1093/ofid/ofy210.819 |
Ejemplares similares
-
1345. Randomized Control Trial to Evaluate the Clinical and Cytokine Response Profile to Oral Thalidomide in Leprosy Patients with Erythema Nodosum Leprosum
por: Chopra, Ajay, et al.
Publicado: (2019) -
Thalidomide and steroid in the management of erythema nodosum leprosum
por: Mishra, S. R. P. K., et al.
Publicado: (2022) -
A Case of Lepromatous Leprosy With Erythema Nodosum Leprosum
por: Park, Lily, et al.
Publicado: (2023) -
Dose-dependent thalidomide induced bradycardia in young erythema nodosum leprosum patient
por: Thangaraju, Pugazhenthan, et al.
Publicado: (2019) -
Etanercept in erythema nodosum leprosum
por: Santos, Julia Rocha Silva, et al.
Publicado: (2017)